Replies to post #470 on Ainos Inc (AIMD)

[fast.money]

~~~ $AMARQ Trader Key Points ~~~ interferon play

- AMARQ holds 5 U.S. patents related to Interferon use

- The company has been successful in acquiring settlements in lawsuits over their patents

- Interferons can be used to treat several kinds of cancers, AIDS, Fibromyalgia, Multiple Sclerosis, HPV, and other autoimmune diseases.

- GMR Data concluded that the cancer-treatment industry has sales upwards to $77.4 billion annually, and that is expected to grow to $143.7 billion by 2023, which means the interferon market for AMARQ has great potential.

- The company is currently seeking regulatory (FDA and others) approval of its low-dose oral interferon treatments for both influenza and hepatitis C viral infections.

- The company trades publicly on the OTC markets in the U.S., and on German markets as well in the Frankfurt, Stuttgart, Berlin-Bremen, and Xetra exchanges.

- Amarillo is headed by Stephen T. Chen, a doctor with over 30 years of experience in pharmacology. This includes finding and developing joint venture agreement opportunities, executing business strategy, and leading start-up companies through regulatory requirements.

- The market capitalization is only $395,711.

- As of the most recent 10-Q, there are only 73.5 million shares outstanding, which means that AMARQ has a very low float.

- Recent data has shown that low-dose interferon-alpha (like AMARQ specializes in) can be used to reduce pulmonary damage in cases where patients are infected with highly pathogenic influenza virus (avian flu, swine flu, and others.

- Following research by Hemispherx Biopharma that stated the importance in using interferons to treat influenza, interferon patents are now in focus by major pharmaceutical companies. AMARQ holds five of these types of patents, which could prove to be a very valuable asset to the company when bigger firms are seeking similar patents.